Evidence map›Paper›PMID 31166461›Full record

ArticleActa cirurgica brasileira2019

Pharmacological modulation of b-adrenoceptors as a new cardioprotective strategy for therapy of myocardial dysfunction induced by ischemia and reperfusion.

Francisco Sandro Menezes-Rodrigues, Paolo Ruggero Errante, José Gustavo Padrão Tavares, Renato Ribeiro Nogueira Ferraz, Walter José Gomes, Murched Omar Taha, Carla Alessandra Scorza, Fúlvio Alexandre Scorza, Afonso Caricati-Neto

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Acta cirurgica brasileira, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Pharmacological Modulation of the CaPharmaceuticals (Basel, Switzerland) · 2023
    Article
  10. Article
  11. Role of cardiac βClinics (Sao Paulo, Brazil) · 2023
    Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Francisco Sandro Menezes-RodriguesPostgraduate Program in Pharmacology, Department of Neurology and Neurosurgery, Universidade Federal de São Paulo, Brazil.
Paolo Ruggero ErrantePostgraduate Program in Pharmacology, UNIFESP, Sao Paulo, SP, Brazil.
José Gustavo Padrão TavaresPostgraduate Program in Pharmacology, UNIFESP, Sao Paulo, SP, Brazil.
Renato Ribeiro Nogueira FerrazPostgraduate Program in Management of Health System, Universidade Nove de Julho, Sao Paulo, SP, Brazil.
Walter José GomesDivision of Cardiovascular Surgery, UNIFESP, Sao Paulo, SP, Brazil.
Murched Omar TahaDepartment of Surgery, UNIFESP, Sao Paulo, SP, Brazil.
Carla Alessandra ScorzaDepartment of Neurology and Neurosurgery, UNIFESP, Sao Paulo, SP, Brazil.
Fúlvio Alexandre ScorzaDepartment of Neurology and Neurosurgery, UNIFESP, Sao Paulo, SP, Brazil.
Afonso Caricati-NetoDepartment of Pharmacology, UNIFESP, Sao Paulo, SP, Brazil.
Fundação de Apoio à Universidade Federal de São Paulo · BRUniversidade Federal de São Paulo · BRUniversidade Nove de Julho · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the cardioprotective response of the pharmacological modulation of β-adrenergic receptors (β-AR) in animal model of cardiac ischemia and reperfusion (CIR), in spontaneously hypertensive (SHR) and normotensive (NWR) rats.

methodsCIR was induced by the occlusion of left anterior descendent coronary artery (10 min) and reperfusion (75 min). The SHR was treated with β-AR antagonist atenolol (AT, 10 mg/kg, IV) 5 min before CIR, and NWR were treated with β-AR agonist isoproterenol (ISO, 0.5 mg/kg, IV) 5 min before CIR.

resultsThe treatment with AT increased the incidence of VA, AVB and LET in SHR, suggesting that spontaneous cardioprotection in hypertensive animals was abolished by blockade of β-AR. In contrast, the treatment with ISO significantly reduced the incidence of ventricular arrhythmia, atrioventricular blockade and lethality in NWR (30%, 20% and 20%, respectively), suggesting that the activation of β-AR stimulate cardioprotection in normotensive animals. Serum CK-MB were higher in SHR/CIR and NWR/CIR compared to respective SHAM group (not altered by treatment with AT or ISO).

conclusionThe pharmacological modulation of β-AR could be a new cardioprotective strategy for the therapy of myocardial dysfunctions induced by CIR related to cardiac surgery and cardiovascular diseases.

Indexed as

Adrenergic beta-1 Receptor AntagonistsAdrenergic beta-AgonistsAnimalsAtenololBiomarkersBlood PressureCardiotonic AgentsCreatine Kinase, MB FormHeart Function TestsIsoproterenolMaleMyocardial Reperfusion InjuryRats, Inbred SHRReceptors, Adrenergic, betaReproducibility of ResultsTime FactorsAdrenergic beta-1 Receptor AntagonistsAdrenergic beta-AgonistsAtenololBiomarkersCardiotonic AgentsCreatine Kinase, MB FormIsoproterenolReceptors, Adrenergic, beta

Identifiers

PMID31166461
PMCPMC6583939
OpenAlexW2947808359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.